Sandip Basu

He is also the Dean-Academic (Health-Sciences), BARC at Homi Bhabha National Institute and is known for his services and research in Nuclear Medicine, particularly on Positron emission tomography diagnostics and Targeted Radionuclide Therapy in Cancer.

[2] He also serves as the dean-academics (Health Sciences), BARC at Homi Bhabha National Institute of the Department of Atomic Energy.

[4][note 2] He is known for his clinical and applied research in the field of Nuclear Medicine, especially on positron emission tomography-based diagnostics and Targeted Radionuclide therapy.

Between 2010 and 2020, Dr. Basu was instrumental in developing a large-volume clinical PRRT service in the centre by the joint efforts of Radiation Medicine Centre (RMC), Bhabha Atomic Research Centre (BARC), and Tata Memorial Hospital (TMH) at the TMH-RMC premises, delivering over 4,000 [177Lu]Lu-DOTATATE therapies for patients with metastatic/advanced neuroendocrine neoplasms and related malignancies making this the largest PRRT set-up in the country, an exemplar of successful PRRT programme employing indigenous 177Lutetium production at BARC and resources.

Since 2017, he steered the development of [68Ga]Ga-/[177Lu]Lu-PSMA-based theranostics and peptide receptor radioligand therapy (PRLT) in metastatic castration resistant prostate carcinoma (mCRPC) patients in the centre.